NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding NextCure, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 44 | 46 | +2 |
| Shares | 15.9M | 16.0M | +170.4K (+1.1%) |
| Value | $21.7M | $13.1M | −$8.60M (−39.6%) |
New holders (8)
Institutions that held NextCure, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pfizer Inc | 1,458,550 | $1.89M | 0.07% |
| Citigroup Inc | 1,389,040 | $1.07M | 0.00% |
| Peapod Lane Capital LLC | 403,698 | $311.3K | 0.31% |
| Susquehanna International Group, LLP | 48,186 | $37.2K | 0.00% |
| Velan Capital Investment Management LP | 25,000 | $19.3K | 0.02% |
| Virtu Financial LLC | 22,951 | $18.0K | 0.00% |
| XTX Topco Ltd | 13,577 | $10.5K | 0.00% |
| Tower Research Capital LLC (TRC) | 658 | $508 | 0.00% |
Sold out (6)
Institutions that held NextCure, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Logos Global Management LP | 2,500,000 | $3.42M |
| Acuitas Investments, LLC | 342,592 | $469.4K |
| Assenagon Asset Management S.A. | 85,308 | $116.9K |
| Walleye Capital LLC | 21,247 | $29.1K |
| HarbourVest Partners LLC | 10,044 | $13.8K |
| Charles Schwab Investment Management Inc | 10,000 | $13.7K |